Gyre Therapeutics (GYRE) Operating Income (2010 - 2026)
Gyre Therapeutics (GYRE) reported Operating Income of -$9.4 million for Q1 2026, down 511.57% year-over-year from $2.3 million in Q1 2025, and down 12.21% quarter-over-quarter from -$8.3 million in Q4 2025.
Gyre Therapeutics (GYRE) Operating Income (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Operating Income data on file, last reported at -$9.4 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$9.4 million, down 511.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.6 million (down 182.93% YoY), and the FY2025 annual result was $3.0 million, down 81.24% from the prior year.
- Operating Income eased to -$9.4 million in Q1 2026 per GYRE's latest filing, from -$8.3 million in the prior quarter.
- Over five years, Operating Income peaked at $51.5 million in Q2 2022 and troughed at -$91.6 million in Q4 2023.
- A 5-year average of -$2.8 million and a median of $2.3 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income soared 358.76% in 2022, then slumped 1353.68% in 2025.
- A 5-year view of Operating Income shows it stood at -$22.5 million in 2022, then sank by 307.98% to -$91.6 million in 2023, then jumped by 100.73% to $665000.0 in 2024, then tumbled by 1353.68% to -$8.3 million in 2025, then retreated by 12.21% to -$9.4 million in 2026.
- Business Quant data shows GYRE's Operating Income at -$9.4 million in Q1 2026, -$8.3 million in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -9.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.36 Mn |
| Dec 31, 2025 | -8.34 Mn |
| Sep 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 665,000.00 |
| Sep 30, 2024 | 4.23 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Mar 31, 2024 | 8.07 Mn |
| Dec 31, 2023 | -91.63 Mn |
| Sep 30, 2023 | 12.76 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 6.66 Mn |
| Dec 31, 2022 | -22.46 Mn |
| Sep 30, 2022 | -5.17 Mn |
| Jun 30, 2022 | 51.53 Mn |
| Mar 31, 2022 | -14.70 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.23 Mn |
| Jun 30, 2021 | -19.91 Mn |